Opposing effects of bisphosphonates and advanced glycation end-products on
osteoblastic cells by Gangoiti, María Virginia et al.
Endocrine Pharmacology
Opposing effects of bisphosphonates and advanced glycation end-products on
osteoblastic cells
María Virginia Gangoiti, Ana María Cortizo, Verónica Arnol,
Juan Ignacio Felice, Antonio Desmond McCarthy ⁎
Bioquímica Patológica, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Argentina
a b s t r a c ta r t i c l e i n f o
Article history:
Received 3 May 2008
Received in revised form 28 September 2008
Accepted 13 October 2008
Available online 21 October 2008
Keywords:
Bisphosphonates
Advanced glycation endproducts
Osteoblasts
Proliferation
Reactive oxygen species
Patients with long-standing Diabetes mellitus can develop osteopenia and osteoporosis. We have previously
shown that advanced glycation endproducts reduce the bone-forming activity of osteoblasts. Bispho-
sphonates are used for the treatment of various bone disorders, since they reduce osteoclastic function and
survival, and stimulate osteoblastic bone-forming capacity. In this work we have investigated whether
bisphosphonates are able to revert advanced glycation endproducts-induced deleterious effects in
osteoblasts. MC3T3E1 and UMR106 osteoblastic cells were incubated with control or advanced glycation
endproducts-modiﬁed bovine serum albumin, in the presence or absence of different doses of the
bisphosphonates Alendronate, Pamidronate or Zoledronate. After 24–72 h of culture, we evaluated their
effects on cell proliferation and apoptosis, type-1 collagen production, alkaline and neutral phosphatase
activity, and intracellular reactive oxygen species production. Advanced glycation endproducts signiﬁcantly
decreased osteoblast proliferation, alkaline phosphatase activity and type 1 collagen production, while
increasing osteoblastic apoptosis and reactive oxygen species production. These effects were completely
reverted by low doses (10−8 M) of bisphosphonates. High doses of bisphosphonates (10−4–10−5 M) were toxic
for osteoblasts. Nifedipine (L-type calcium channel blocker) did not affect the advanced glycation
endproducts-induced decrease in osteoblastic proliferation, although it blocked the reversion of this effect
by 10−8 M Alendronate. Both advanced glycation endproducts and Alendronate inhibited the activity of
intracellular neutral phosphatases. In conclusion, we show that bisphosphonates revert the deleterious
actions of advanced glycation endproducts on osteoblastic cells, and that these effects of bisphosphonates
depend on: (a) Ca2+ inﬂux through L-type voltage-sensitive channels, and (b) blockage of advanced glycation
endproducts-induced reactive oxygen species generation.
© 2008 Elsevier B.V. All rights reserved.
1. Introduction
Bisphosphonates are drugs which have been extensively used for
the treatment of bone disorders such as osteoporosis, Paget's disease,
and tumor-associated osteolysis and hypercalcemia (Rogers, 2003).
Bisphosphonates have a similar chemical structure to that of inorganic
pyrophosphate, in which the P–O–P bond, which links the two
phosphate groups, is replaced by a carbon atom (P–C–P structure).
Bisphosphonates have a structural motif in common, called the “bone
hook”, which consists of the two phosphonate groups that facilitate
binding to bone mineral (Green, 2005). The exact molecular targets
and mechanisms of action of bisphosphonates have remained unclear
for more than 30 years, but have recently begun to be unraveled. Thus,
bisphosphonates can be grouped into two classes with different
molecular mechanisms of action. Nitrogen-containing bisphospho-
nates are the most potent kind, and act by inhibiting the mevalonate
pathway, thereby preventing prenylation of small GTPase signaling
proteins. On the other hand, bisphosphonates that lack a nitrogen in
their chemical structure are less potent and have a different mode
of action that may involve the formation of cytotoxic metabolites or
inhibition of protein tyrosine phosphatases (Rogers et al., 2000).
Bisphosphonates have been shown to affect bone metabolism
mainly by inhibiting osteoclast-mediated bone resorption (Rogers,
2003). More recently, increasing lines of evidence have also implicated
other bone cell types such as osteoblasts as possible targets for direct
and indirect action of bisphosphonates (Tsuchimoto et al., 1994;
Viereck et al., 2002), although the precise mechanisms have not been
elucidated. In this line of work, our group has previously shown a
biphasic effect of bisphosphonates on osteoblastic growth and
differentiation, with an increase in both parameters at low concentra-
tions of bisphosphonates, and a decrease at 10−4–10−5 M (Vaisman
et al., 2004). The latter decrease may be partly due to an inhibitory
effect of bisphosphonates which we have shown on osteoblastic
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neutral phosphatases (Molinuevo et al., 2007) and on alkaline
phosphatase via chelation of divalent cations (Vaisman et al., 2005).
In a series of elegant experiments, Plotkin et al. (1999, 2006) have
demonstrated that bisphosphonates can prevent osteoblast and
osteocyte apoptosis in vivo and in vitro, and have proposed that
their anti-fracture actions could result in part from a preservation of
the integrity of the osteocyte network, and/or from an increase in the
working time of bone forming cells.
Diabetes mellitus has been shown to affect the integrity and
functionality of bone tissue (Bouillon, 1991; Schwartz, 2003). Patients
with type 1 diabetes frequently show low bone mass (osteopenia)
mainly caused by a decrease in bone formation, with a reduction in the
number and activity of osteoblasts. On the other hand, type 2 diabetes is
simultaneously associated both with an increase in bone mineral
density, and with an increased risk of fracture and impaired bone
healing (Schwartz et al., 2001; Strotmeyer et al., 2005), thus indicating
an overall decrease in bone architecture and quality. It has recently
been reported that diabetes enhances the apoptosis of ﬁbroblasts and
osteoblasts mainly by activating caspase-8, -9 and -3 expression and
activity, which in turnmay impair bone healing (Al-Mashat et al., 2006).
The accumulation of advanced glycation endproducts is believed
to play a pathogenic role in the development of different long-term
complications of both types of diabetes (Brownlee, 2005). Advanced
glycation endproducts are slowly and irreversibly formed on proteins
exposed to carbonyl and substrate stress, especially in conditions of
hyperglycaemia, hyperlipidaemia and/or oxidative stress. Long lived
proteins such as collagen are the main targets for advanced glycation
endproducts formation. In particular, advanced glycation endpro-
ducts-mediated collagen overcrosslinking can cause loss of ﬂexibility
and elasticity and increased brittleness of tissues like bone (Ulrich and
Cerami, 2001).
We have previously shown that soluble and matrix-associated
advanced glycation endproducts can modulate osteoblastic growth
and differentiation (McCarthy et al., 1997, 2001). In those experiments,
we demonstrated that long-term exposure to advanced glycation
endproducts-modiﬁed proteins signiﬁcantly inhibited the prolifera-
tion, differentiation and mineralization of osteoblastic cultures. We
also found that the advanced glycation endproducts-induced osteo-
blastic effects could bemediated by speciﬁc receptors such as receptor
for advanced glycation endproducts-1 (McCarthy et al., 1999; Cortizo
et al., 2003). Interestingly, other authors have recently reported that
advanced glycation endproducts can stimulate osteoblast apoptosis
through their interaction with receptor for advanced glycation end-
products-1, via the MAP kinase signaling pathway and caspase-8
activation of caspase-3 (Alikhani et al., 2007).
In the present study we have evaluated whether N-containing
bisphosphonates are able to revert the deleterious effects of advanced
glycation endproducts on osteoblasts in culture. To address this issue
we have investigated the effects of advanced glycation endproducts
with or without different bisphosphonates, on osteoblastic prolifera-
tion, differentiation, apoptosis, intracellular oxidative stress and
neutral phosphatase activity in two osteoblastic cell lines in culture.
2. Materials and methods
2.1. Materials
Alendronate [1-hydroxy-3-aminobutylidene-1,1-bisphosphonic
acid] was provided by Elea Laboratories (Argentina); Pamidronate
[1-hydroxy-3-aminopropylidene-1,1-bisphosphonic acid, disodium
salt] and Zoledronate [2-(imidazol-1-yl)-hydroxyethylidene-1,1-
bisphosphonic acid, disodium salt] were provided by Novartis (Basel,
Switzerland). Dulbecco's modiﬁed Eagle's medium (DMEM), trypsin–
EDTA and foetal bovine serum were obtained from Gibco (Invitrogen,
Buenos Aires, Argentina). Tissue culture disposable material was
from Nunc (Tecnolab, Buenos Aires, Argentina). Centricon 10 kDa
cutoff ﬁlter cartridges were purchased from Amicon Inc. (Beverly,
Mass., USA). Bovine serum albumin, D-glycolaldehyde, Triton X-100
and Sirius Red dye were obtained from Sigma-Aldrich (Buenos Aires,
Argentina). Di-hydro-rhodamine 123 (DHR), annexin V-FITC, propi-
dium iodide (PI) and ﬂuorogenic small substrate 6,8-diﬂuoro-4-
methylumbelliferyl 86 phosphate (DiFMUP) were from Molecular
Probes (Buenos Aires, Argentina). All other chemicals and reagents
werepurchased fromcommercial sources andwere of analytical grade.
2.2. Preparation of advanced glycation endproducts
Advanced glycation endproducts-modiﬁed bovine serum albumin
was prepared by incubation of 10 mg/ml bovine serum albumin
with 33 mM D-glycolaldehyde in 150 mM phosphate-buffered saline
pH 7.4 at 37 °C for 3 days under sterile conditions (Unno et al., 2004).
D-glycolaldehyde was used as the glycating sugar instead of glucose to
speed up non-enzymatic glycosylation. Control bovine serum albumin
was incubated in the same conditions without sugar. The unincorpo-
rated sugar was removed by centrifugation/ﬁltration with Centricon
ﬁlter cartridges. The formation of advanced glycation endproducts
was assessed with an Aminco-Bowman SPF100 spectroﬂuorometer by
their characteristic ﬂuorescence-emission maximum at 420 nm upon
excitation at 340 nm. The estimated levels of advanced glycation
endproducts-modiﬁed bovine serum albumin obtained in this in vitro
incubation were 18.5% relative ﬂuorescence intensity/mg protein, in
contrast to 3.2% for control bovine serum albumin.
2.3. Cell cultures and incubations
UMR106 rat osteosarcoma cells and MC3T3E1 mouse calvaria-
derived cells were grown in DMEM containing 10% foetal bovine
serum,100 U/ml penicillin and 100 μg/ml streptomycin at 37 °C in a 5%
CO2 atmosphere (McCarthy et al., 1997). Cells were seeded on 75 cm2
ﬂasks, sub-cultured using trypsin–EDTA and replated on multi-well
plates. The UMR106 rat osteosarcoma-derived cell line has been
shown to conserve certain characteristics of differentiated osteoblas-
tic phenotype (Partridge et al., 1983). In the case of non-transformed
MC3T3E1 mouse calvaria-derived osteoblastic cells, previous studies
have demonstrated that expression of osteoblastic markers begins
after culturing the cells with medium supplemented by 5 mM β-
glycerol-phosphate and 25 μg/ml ascorbic acid (Quarles et al., 1992).
Under these culture conditions, alkaline phosphatase activity begins
to be expressed after 1 week, while mineralization is achieved after
extending the culture to 3 weeks. However, the cells only undergo
active replication during the ﬁrst 5 days of incubation. For prolifera-
tion, apoptosis and reactive oxygen species formation experiments
in both cell lines, and differentiation experiments with UMR106
osteoblasts, cells seeded on multi-well plates were incubated in
DMEM medium with different doses of bovine serum albumin or
advanced glycation endproducts-modiﬁed bovine serum albumin,
with orwithout bisphosphonates, during the periods of time indicated
in the legends of ﬁgures. For alkaline phosphatase expression experi-
ments with MC3T3E1 osteoblasts, cells were cultured for 1 week in
DMEM/Foetal bovine serum supplemented with β-glycerol-phos-
phate and ascorbic acid changing the medium every 2 days, after
which they were serum-starved and incubated in DMEM with
different doses of bovine serum albumin or advanced glycation
endproducts-modiﬁed bovine serum albumin, with or without
bisphosphonates, for an additional 72 h.
2.4. Assays for osteoblast proliferation
Cell proliferation was determined using the crystal violet mito-
genic bioassay as described previously (Okajima et al., 1992), with
some modiﬁcations. Brieﬂy, cells were grown in 48-well plates and
submitted to different experimental conditions in serum-free DMEM,
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according to the ﬁgure legends. Then, the monolayers were washed
with phosphate-buffered saline and ﬁxed with 5% glutaraldehyde/
phosphate-buffered saline at room temperature for 10 min. After that,
they were stained with 0.5% crystal violet/25% methanol for 10 min.
The dye taken up by the cells was extracted using 0.5 ml/well 0.1 M
glycine/HCl buffer, pH 3.0/30% methanol and transferred to test tubes.
Absorbance was read at 540 nm after a convenient sample dilution.
We have previously shown that, under these conditions, this color-
imetric bioassay strongly correlates with cell proliferation measured
by cell counting in Neubauer chambers (Cortizo and Etcheverry, 1995).
In order to evaluate the possible role of calcium in the modulation of
osteoblastic proliferation by advanced glycation endproducts and/or
bisphosphonates, in certain experiments we also included 10 μM
Nifedipine in the incubation media.
2.5. Assays for osteoblast differentiation
Osteoblastic differentiation was evaluated by measuring alkaline
phosphatase activity and type I collagen production. Alkaline phos-
phatase activity was assayed as we have previously described (Cortizo
and Etcheverry, 1995). Brieﬂy, the cell layer was washed with phos-
phate-buffered saline and solubilized in 0.5 ml 0.1% Triton X-100.
Aliquots of the total cell extract were used for protein determination
by the Bradford technique (Bradford, 1976). Measurement of alkaline
phosphatase was carried out by spectrophotometric determination
of initial rates of hydrolysis of para-nitrophenyl-phosphate (p-NPP) to
para-nitrophenol (p-NP) at 37 °C for 10 min. The production of p-NP
was determined by absorbance at 405 nm. Under our experimental
conditions p-NP formation was linear for 15 min. Collagen pro-
duction was evaluated with a Sirius red-based colorimetric micro-
assay (Tullberg-Reinert and Jundt, 1999): cells were ﬁxed in Bouin's
ﬂuid for 1 h, washedwithwater and stainedwith Sirius red dye for 1 h.
The stained material was dissolved in 0.1 N sodium hydroxide and
absorbance read at 550 nm.
2.6. Evaluation of cell death
Apoptosis was evaluated using an annexin V-FITC/propidium
iodide (PI) assay as we have previously described (Molinuevo et al.,
2004). Early apoptotic stages were characterized by annexin V-FITC-
positive/PI-negative (V+/PI−) staining, while apoptotic/necrotic stages
were V+/PI+. The percentage of apoptotic and necrotic osteoblasts was
determined by counting the cells per ﬁeld in 20 ﬁelds per coverslip.
2.7. Determination of intracellular reactive oxygen species formation
Intracellular reactive oxygen species generation in osteoblastic
cells was measured by oxidation of dihydro-rhodamine123(DHR) to
rhodamine as we have previously described (McCarthy et al., 2001).
Osteoblastic cell monolayers growing in 24-well plates were sub-
mitted to the culture conditions indicated in ﬁgure legends. Medium
was replaced by phenol red-free DMEM with 10 μM DHR and the
cells were further incubated for 4 h. After washing with phosphate-
buffered saline, the monolayer was lysated in 0.1% Triton X-100.
Fig. 1. Effect of advanced glycation endproducts (AGEs) and bisphosphonates on osteoblast proliferation. MC3T3E1 (A and B) or UMR106 (C andD) osteoblastic cells were incubated for
24hwith 100 µg/ml of either bovine serumalbumin (BSA) (A and C) or AGEs-BSA (B andD),with orwithout different concentrations (10−4,10−6 or 10−8M) of Alendronate, Pamidronate
or Zoledronate. Cell proliferationwas determined by the Crystal Violetmethod. Results have been referred to basal conditions (BSA alone), and are shown as themean±S.E.M. ⁎Pb0.01.
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The concentration of oxidized product present in the cell extract
(rhodamine), was determined with a spectroﬂuorometer (excitation
wavelength 495 nm, emission wavelength 532 nm).
2.8. Fluorogenic phosphatase assay
In order to evaluate the effect of advanced glycation endproducts and
bisphosphonates on the activity of osteoblastic neutral phosphatases, we
carried out a ﬂuorogenic assay. This assay was performed by incubating
conﬂuent UMR106 monolayers with 200 μg/ml of either bovine serum
albumin or advanced glycation endproducts-modiﬁed bovine serum
albumin plus different concentrations (10−4, 10−5 or 10−6 M) of
Alendronate for 24 h. After that, an aliquot of cell lysates (50 μg of protein)
were incubated with the ﬂuorogenic substrate DiFMUP for 10 min as
previously described (Molinuevo et al., 2007). The resulting ﬂuorescent
product was measured every minute at 360/450 nm (excitation/emission
wavelengths) using an Aminco-Bowman SPF100 spectroﬂuorometer.
2.9. Statistical analysis
The results are expressed as the mean±S.E.M. and were obtained
from three separate experiments performed in triplicate. Differences
between the groups were assessed by Oneway ANOVA with Tukey
post-hoc test. For non-normally distributed data, non-parametrical
Kruskal Wallis with Dunn post-hoc test was performed using
GraphPad In Stat version 3.00 (Graph Pad Software, San Diego,
California, USA). A P value b0.05 was considered signiﬁcant for all
statistical analyses.
3. Results
3.1. Modulation of osteoblast proliferation. Role of intracellular calcium
MC3T3E1 and UMR106 osteoblastic cells were incubated for 24 h
with 100 µg/ml of either bovine serum albumin or advanced glycation
Fig. 2. Role of calcium in the modulation of osteoblastic proliferation by advanced
glycation endproducts (AGEs) and bisphosphonates. MC3T3E1 osteoblasts were pre-
incubated for 10 h in the presence or absence of 10 μM of the calcium channel inhibitor
Nifedipine (with or without 10−8 M Alendronate), after which 100 µg/ml of either
bovine serum albumin (BSA) or AGEs-BSA were added to the culture medium for an
additional 14 h. Cell proliferation was determined by the Crystal Violet method. Results
have been referred to basal conditions (BSA alone), and are shown as the mean±S.E.M.
⁎Pb0.01.
Fig. 3. Effect of advanced glycation endproducts (AGEs) and bisphosphonates on the
induction of apoptosis in osteoblastic cells. UMR106 or MC3T3E1 osteoblastic cells were
incubated for 24hwith100 µg/ml of either bovine serumalbumin (BSA) orAGEs-BSA,with or
without 10−8 M of Alendronate. Apoptosis was evaluated by Annexin V/Propidium Iodide
staining, as described in Materials and methods. The percentage of apoptotic and necrotic
osteoblastswasdeterminedbycounting thenumberof cells perﬁeld in20ﬁeldspercoverslip.
Results havebeen referred tobasal conditions (BSAalone), and are shownas themean±S.E.M.
⁎Pb0.01.
Fig. 4. Effect of advanced glycation endproducts (AGEs) and bisphosphonates on the
differentiation of osteoblastic cells. MC3T3E1 osteoblasts (pre-treated with β-glycerol-
phosphate and ascorbic acid for a week) or 48 h cultures of UMR106 cells were further
incubated for 72hwith100 µg/ml of either bovine serumalbumin (BSA) orAGEs-BSA,with or
without 10−8MAlendronate. Asdescribed inMaterials andmethods, both cell lineswere then
evaluated for alkaline phosphatase expression (A), and for type 1 collagen production (B).
Results havebeen referred tobasal conditions (BSAalone), and are shownas themean±S.E.M.
⁎Pb0.01.
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endproducts-modiﬁed bovine serum albumin, with or without dif-
ferent concentrations (10−8, 10−6 or 10−4 M) of Alendronate,
Pamidronate or Zoledronate. These concentrations were chosen be-
cause in patients under treatment for osteoporosis with bispho-
sphonates, osteoblasts are believed to be exposed to levels equal or
lower than 10−5 M (Spreaﬁco et al., 2006). After this incubation period,
cell proliferation was evaluated by the Crystal Violet method. As can
be seen in Fig. 1, advanced glycation endproducts-modiﬁed bovine
serum albumin signiﬁcantly diminished osteoblast proliferation, and
this decrease was reverted by co-incubation with 10−8 or 10−6 M
Alendronate, Pamidronate or Zoledronate. However, co-incubation
with higher concentrations (10−4 M) of all three bisphosphonates was
toxic for osteoblasts, and this effect was independent of the presence
of bovine serum albumin or advanced glycation endproducts-
modiﬁed bovine serum albumin (Fig. 1). To evaluate the participation
of intracellular calcium in this phenomenon, in some experiments we
pre-incubated cells for 10 h with 10 μM of the L-type voltage-sensitive
calcium channel inhibitor Nifedipine (with or without 10−8 M
Alendronate), after which we added 100 µg/ml of either bovine
serum albumin or advanced glycation endproducts-modiﬁed bovine
serum albumin to the culture medium for an additional 14 h. We
found that although Nifedipine did not alter the advanced glycation
endproducts-induced decrease in osteoblastic proliferation, it com-
pletely abrogated the Alendronate-dependent reversion of advanced
glycation endproducts effects on osteoblastic growth (Fig. 2).
3.2. Effect of advanced glycation endproducts and bisphosphonates on
osteoblast apoptosis
We postulated that the modulation of osteoblastic proliferation
by advanced glycation endproducts and bisphosphonates could be at
least partly due to opposing effects on the induction of cell apoptosis.
Thus, MC3T3E1 and UMR106 osteoblastic cells were incubated
for 24 h with 100 µg/ml of either control or advanced glycation end-
products-modiﬁed bovine serum albumin, with or without 10−8 M
Alendronate, after which they were evaluated for induction of apo-
ptosis by the Annexin V/PI method as described in Materials and
methods. Fig. 3 shows that in both osteoblastic cell lines advanced
glycation endproducts induced a signiﬁcant increase in apoptosis,
which was however completely reverted by Alendronate.
3.3. Effects of advanced glycation endproducts and bisphosphonates on
osteoblast differentiation
We next evaluated the effect of advanced glycation endproducts and
bisphosphonates on the differentiation of osteoblastic cells. For this,
MC3T3E1 osteoblasts (pre-treated with β-glycerol-phosphate and
ascorbic acid for a week) or 48 h cultures of UMR106 osteosarcoma-
derived cells were further incubated for 72 h with 100 µg/ml of either
control or advanced glycation endproducts-modiﬁed bovine serum
albumin, with or without 10−8 M Alendronate. After this incubation,
both cell lines were evaluated for alkaline phosphatase expression and
for type 1 collagen production, as described in Materials and methods.
As canbeseen inFig. 4, in bothcell lines advancedglycation endproducts
signiﬁcantly decreased alkaline phosphatase expression and type 1
collagen production. However, both deleterious effects were completely
abrogated by co-incubation with Alendronate.
3.4. Effect of advanced glycation endproducts and bisphosphonates on
intracellular reactive oxygen species production
Intracellular reactive oxygen species production is known tomediate
certain effects of advanced glycation endproducts, particularly those
Fig. 5. Effect of advanced glycation endproducts (AGEs) and bisphosphonates on
intracellular reactive oxygen species production. MC3T3E1 osteoblasts were incubated
24 hwith 100 µg/ml of either bovine serum albumin (BSA) or AGEs-BSA, with orwithout
10−8 M Alendronate (Ale) and in the presence or absence of 50 μM of vitamins C and E
(as anti-oxidants). Osteoblasts were then evaluated for intracellular reactive oxygen
species production by the DHR method, as described in Materials and methods. Results
have been referred to basal conditions (BSA alone), and are shown as the mean±S.E.M.
⁎Pb0.01.
Fig. 6. Effect of advanced glycation endproducts (AGEs) and bisphosphonates on the
activity of osteoblastic neutral phosphatases. Conﬂuent monolayers of UMR106
osteoblastic cells were incubated for 24 h with 200 μg/ml of bovine serum albumin
(BSA) or AGEs-BSA, plus different concentrations (10−4, 10−5 or 10−6 M) of Alendronate
(Ale). Aliquots of cell lysates (50 μg of protein) were then incubated for 10 min with the
ﬂuorogenic substrate DiFMUP, and the resulting ﬂuorescent product was measured
every minute as described in Materials and methods. For each experimental condition,
slopes were calculated by regression analysis in order to determine the activity of total
neutral phosphatases, and these are shown in Table 1.
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which depend on recognition of advanced glycation endproducts by the
receptor of advanced glycation endproducts. Thus,we set out to evaluate
whether this signal transduction pathway is involved in themodulation
of osteoblasts by advanced glycation endproducts and bisphosphonates.
For this, we incubated osteoblastic cells with 100 µg/ml of either bovine
serum albumin or advanced glycation endproducts-modiﬁed bovine
serumalbumin,with orwithout10−8MAlendronate and in thepresence
or absence of 50 μM of vitamins C and E (as anti-oxidants), after which
the osteoblasts were evaluated for intracellular reactive oxygen species
production by the DHR method. Fig. 5 shows that osteoblastic cells
exposed to advanced glycation endproducts signiﬁcantly increased
their intracellular production of reactive oxygen species. However, this
increase was completely curbed in the presence of Alendronate and/or
anti-oxidants.
3.5. Effect of advanced glycation endproducts and bisphosphonates on
the activity of neutral phosphatases
In this study we also evaluated the modulation of intracellular
neutral phosphatases by bisphosphonates, as another possible mecha-
nism for the regulation of osteoblastic development. For this, con-
ﬂuent monolayers of osteoblastic cells were incubated for 24 h with
control or advanced glycation endproducts-modiﬁed bovine serum
albumin, plus different concentrations of Alendronate. Cell lysates
were then obtained and aliquots were incubated for 10 min with the
ﬂuorogenic substrate DiFMUP: the activity of total neutral phospha-
tases was determined by the rate of appearance of the ﬂuorescent
product. As can be seen in Fig. 6 and Table 1, we found that advanced
glycation endproducts alone (Fig. 6B) inhibited neutral phosphatases
activity by half (versus bovine serum albumin alone, Fig. 6A) and that
this inhibition was similar to that observed for bovine serum albumin
plus 10−6 M Alendronate. However, there was no difference in neutral
phosphatases activity between advanced glycation endproducts alone
and advanced glycation endproducts plus 10−6 M Alendronate (Fig. 6B).
In the case of higher doses of Alendronate (10−5 and 10−4 M), which
are compatible with a signiﬁcant chelation of divalent cations, a dose-
dependent inhibition of neutral phosphatases activity was observed
with both bovine serum albumin and advanced glycation endproducts-
modiﬁed bovine serum albumin.
4. Discussion
Advanced glycation endproducts accumulate in various tissues
in patients with Diabetes mellitus, and have been implicated in the
development and progression of diabetic chronic complications
(Ulrich and Cerami, 2001; Brownlee, 2005). These complications
include a decrease in bone formation and turnover, which has been
studied by various authors (Bouillon, 1991; Krakauer et al., 1995;
Schwartz, 2003). In particular, Krakauer et al. (1995) in a 12-year
follow-up clinical study, showed that osteoblastic extracellular matrix
production and mineralization was signiﬁcantly impaired in patients
with type 1 and type 2 Diabetes mellitus. Although the precise
mechanisms by which long-standing Diabetes may affect bone are
incompletely known, the accumulation of advanced glycation end-
products in bone tissue is believed to be one of the main culprits
(Schwartz, 2003). We have previously shown that advanced glycation
endproducts can directly affect the growth and differentiation of
osteoblasts (McCarthy et al., 1997, 2001). These actions seem to be
mediated through the activation of speciﬁc receptors for advanced
glycation endproducts, which we have described in osteoblastic cells
(McCarthy et al., 1999; Cortizo et al., 2003).
Bisphosphonates are probably the most widely used family of anti-
osteoporotic drugs, and although their primary actions target osteo-
clastic function and survival, they have also recently been shown to
positively inﬂuence osteoblastic development and bone-forming
potential (Tsuchimoto et al., 1994; Plotkin et al., 1999; Viereck et al.,
2002). Bisphosphonates are utilized in patients with Diabetes mellitus
and osteoporosis, although with conﬂicting results (Dagdelen et al.,
2007; Yamauchi, 2007). Recently, an anti-advanced glycation end-
products effect of N-containing bisphosphonates has been postulated
(Yamagishi et al., 2006): in experiments with human umbilical vein
endothelial cells (HUVECS), Yamagishi and co-workers have shown
that Incadronate and Minodronate can revert deleterious effects of
advanced glycation endproducts (Okamoto et al., 2002; Yamagishi
et al., 2005). This beneﬁcial action of these bisphosphonates was
found to be due to a suppression of NADPH oxidase-derived intra-
cellular reactive oxygen species generation, probably via inhibition of
geranyl-geranylation of Rac: NADPH oxidase-derived reactive oxygen
species generation is required for advanced glycation endproducts-
Receptor for advanced glycation endproducts signaling in vascular
wall cells, and small G protein Rac is a critical component of the
NADPH oxidase complex.
Since orally absorbed bisphosphonates primarily localize to sites of
actively remodeling bone tissue, in this work we set out to investigate
whether N-containing bisphosphonates could revert the deleterious
effects of advanced glycation endproducts on osteoblasts, which we
have described previously (McCarthy et al., 1997, 2001). Our present
results support this hypothesis, and evidence for this notion is based on
the following observations: (a) advanced glycation endproducts induce
in osteoblasts both an increase in apoptosis and a decrease in cell
proliferation, and both effects are reverted by low doses of bispho-
sphonates. (b) advanced glycation endproducts impair osteoblastic
bone-forming potential since they diminish both alkaline phosphatase
speciﬁc activity and type 1 collagen production; however, these dele-
terious actions of advanced glycation endproducts are completely
abrogated by low concentrations of bisphosphonates.
This reversion by bisphosphonates of the anti-proliferative effect
of advanced glycation endproducts, can be at least partly accounted
for by the anti-apoptotic action of bisphosphonates which we show in
the present work, and which has also been reported by other authors
(Plotkin et al., 1999, 2006). However, it could also be due to apoptosis-
independent mechanisms. Mathov et al. (2001) have demonstrated
that bisphosphonates can directly increase the proliferation of osteo-
blasts via activation of extracellular signal-regulated kinases and
calcium inﬂux. This led us to investigate whether in our culture con-
ditions the effects of bisphosphonates on osteoblast proliferationwere
calcium-dependent: using Nifedipine we have shown that although
the anti-proliferative effects of advanced glycation endproducts are
calcium-independent, the reversion of such effects by bisphospho-
nates requires inﬂux of Ca2+ through L-type voltage-sensitive calcium
channels.
Different authors have investigated the direct modulation by
N-containing bisphosphonates of osteoblastic alkaline phosphatase
activity and type 1 collagen expression. Overall, they have found that
bisphosphonates induce a signiﬁcant increase in both parameters of
osteoblast differentiation (Fromigué and Body, 2002; Spreaﬁco et al.,
2006; Boanini et al., 2008). These observations are in agreement with
Table 1
Effect of bovine serum albumin (BSA), advanced glycation endproducts (AGEs) and
different doses of Alendronate on the activity rate of total neutral phosphatases in
UMR106 osteoblastic cells
Condition Activity rate Activity rate
[as % of BSA 200] [as % of AGEs 200]
BSA 200 µg/ml 100 –
BSA 200+10−6 M Alendronate 57 –
BSA 200+10−5 M Alendronate 41 –
BSA 200+10−4 M Alendronate 32 –
AGEs 200 µg/ml 43 100
AGEs 200+10−6 M Alendronate 45 103
AGEs 200+10−5 M Alendronate 36 83
AGEs 200+10−4 M Alendronate 27 63
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our present results, in which we have found a complete reversal by
Alendronate of the inhibition by advanced glycation endproducts of
osteoblastic alkaline phosphatase speciﬁc activity and type 1 collagen
production.
All in all, if our present results could be extrapolated to a clinical
setting, they would signify a return to normality both in the working
time and in the maturation of osteoblasts exposed simultaneously
to an advanced glycation endproducts-enriched bone extracellular
matrix and to N-containing bisphosphonates, possibly leading to an
adequate osteoblastic bone-forming capacity.
In an attempt to deﬁne molecular mechanisms which could
be operating for both advanced glycation endproducts and bispho-
sphonates in osteoblasts, we evaluated the intracellular production
of reactive oxygen species and found that 10−8 M Alendronate com-
pletely curbed the advanced glycation endproducts-induced increase
in reactive oxygen species production. These results are in agreement
with the reports of other authors, in which HUVECS were cultured
with advanced glycation endproducts and bisphosphonates (Okamoto
et al., 2002; Yamagishi et al., 2005): in their culture conditions,
bisphosphonates were found to suppress the advanced glycation
endproducts-induced NADPH oxidase-derived intracellular reactive
oxygen species generation, via inhibition of geranyl-geranylation
of Rac. Although we have not directly proven it, the same modulation
of signal transduction mechanisms is probably operating under our
experimental conditions.
We have previously shown that different doses of bisphosphonates
can inhibit both neutral and alkaline osteoblastic phosphatases (Vais-
man et al., 2005;Molinuevo et al., 2007). In addition, other investigators
have demonstrated that intracellular protein phosphorylation is
essential for the process of osteoblastic differentiation (Xiao et al.,
2002). Thus, in the present work we evaluated the possible modulation
of total osteoblastic neutral phosphatase activity by advanced glycation
endproducts and bisphosphonates. Our present results are com-
patible with the following interpretation: high doses of Alendronate
(10−5–10−4 M) could be inhibiting neutral phosphatases which are
dependent on divalent cations for their function. On the other hand,
both advanced glycation endproducts and lower doses of Alendronate
(10−6M) could be inhibitingmainly divalent cation-independentneutral
phosphatases (such as tyrosine phosphatases). Interestingly, we have
previously shown that osteoblastic neutral phosphatase activity
decreases by 45% in the presence of Vanadate (an inhibitor of tyrosine
phosphatases) (Molinuevo et al., 2007), which is a degree of inhibition
similar to thatwhichwehave found for advanced glycation endproducts
and for 10−6 M Alendronate in the present study.
In conclusion, in the present studywe have shown that N-containing
bisphosphonates are effective in reverting the deleterious actions
of advanced glycation endproducts on osteoblasts in culture, and
that these effects of bisphosphonates depend on: (a) inﬂux of Ca2+
through L-type voltage-sensitive calcium channels, and (b) blockage of
intracellular reactive oxygen species generation. In addition, we have
found that both advanced glycation endproducts and bisphosphonates
can inhibit the activity of intracellular neutral phosphatases. Although
further studies are required to evaluate whether these effects of
bisphosphonates are operative in vivo and in a clinical setting, our
ﬁndings support the results of reports which show a beneﬁcial action of
N-containing bisphosphonates in patients with Diabetes mellitus and
osteoporosis (Yamauchi, 2007).
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